Carla Casulo, MD

Carla Casulo, MD, associate professor in the department of medicine at the University of Rochester Medical Center, discusses the challenges surrounding the treatment of patients with relapsed/refractory follicular lymphoma (FL).

There is no clear way to distinguish which patients will do poorly after treatment, and there&rsquo;s also no biomarkers to determine the response, says Casulo. With a plethora of options available, a physician might select therapy based on when the patient recurs; if a patient recurred early, those patients can be treated more aggressively, but an older patient might need to be considered for a more gentle approach.

Videos

Carla Casulo, MD, discusses the challenges surrounding the treatment of patients with relapsed/refractory follicular lymphoma.

Analyzing Challenges in Treating Patients With Relapsed/Refractory Follicular Lymphoma

Carla Casulo, MD, associate professor in the department of medicine at the University of Rochester Medical Center, discusses recent research for new frontline options for patients with newly diagnosed follicular lymphoma (FL).

A large randomized study looked at frontline treatment with the combination lenalidomide (Revlimid) plus rituximab (Rituxan) compared to standard chemotherapy. The study aimed to establish non-inferiority, but it was found that the 2 regimens were not dramatically different, says Casulo.

Carla Casulo, MD, discusses recent research for new frontline options for patients with newly diagnosed follicular lymphoma.

Carla Casulo, MD | Authors

Articles

Analyzing Challenges in Treating Patients With Relapsed/Refractory Follicular Lymphoma

Ongoing Research for New Frontline Treatments in Follicular Lymphoma